Our work suggests PRMT5 inhibitors could be used in combination with chemotherapy or PARP inhibitors to treat ovarian or breast cancers, including in genetically proficient tumors through the induction of chemically induced synthetic lethality. The gene discussed is PRMT5; the disease is breast carcinoma.